These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cligosiban, A Novel Brain-Penetrant, Selective Oxytocin Receptor Antagonist, Inhibits Ejaculatory Physiology in Rodents. Wayman C; Russell R; Tang K; Weibly L; Gaboardi S; Fisher L; Allers K; Jackson M; Hawcock T; Robinson N; Wilson L; Gupta J; Casey J; Gibson KR J Sex Med; 2018 Dec; 15(12):1698-1706. PubMed ID: 30527053 [TBL] [Abstract][Full Text] [Related]
6. Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists. Quattropani A; Dorbais J; Covini D; Pittet PA; Colovray V; Thomas RJ; Coxhead R; Halazy S; Scheer A; Missotten M; Ayala G; Bradshaw C; De Raemy-Schenk AM; Nichols A; Cirillo R; Tos EG; Giachetti C; Golzio L; Marinelli P; Church DJ; Barberis C; Chollet A; Schwarz MK J Med Chem; 2005 Dec; 48(24):7882-905. PubMed ID: 16302826 [TBL] [Abstract][Full Text] [Related]
7. The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists. Chan WY; Wo NC; Manning M Am J Obstet Gynecol; 1996 Nov; 175(5):1331-5. PubMed ID: 8942510 [TBL] [Abstract][Full Text] [Related]
8. Effects of the non-peptide inhibitor OPC-21268 on oxytocin and vasopressin stimulation of rat and human myometrium. Atke A; Vilhardt H; Hauzerova L; Barth T; Andersen LF Eur J Pharmacol; 1995 Jul; 281(1):63-8. PubMed ID: 8566118 [TBL] [Abstract][Full Text] [Related]
9. 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. Williams PD; Anderson PS; Ball RG; Bock MG; Carroll L; Chiu SH; Clineschmidt BV; Culberson JC; Erb JM; Evans BE J Med Chem; 1994 Mar; 37(5):565-71. PubMed ID: 8126695 [TBL] [Abstract][Full Text] [Related]
10. Receptors for and myometrial responses to oxytocin and vasopressin in preterm and term human pregnancy: effects of the oxytocin antagonist atosiban. Bossmar T; Akerlund M; Fantoni G; Szamatowicz J; Melin P; Maggi M Am J Obstet Gynecol; 1994 Dec; 171(6):1634-42. PubMed ID: 7802081 [TBL] [Abstract][Full Text] [Related]
11. The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. Borthwick AD; Liddle J Med Res Rev; 2011 Jul; 31(4):576-604. PubMed ID: 20027670 [TBL] [Abstract][Full Text] [Related]
12. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency. Borthwick AD; Davies DE; Exall AM; Hatley RJ; Hughes JA; Irving WR; Livermore DG; Sollis SL; Nerozzi F; Valko KL; Allen MJ; Perren M; Shabbir SS; Woollard PM; Price MA J Med Chem; 2006 Jul; 49(14):4159-70. PubMed ID: 16821776 [TBL] [Abstract][Full Text] [Related]
13. The Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the Response of Human Myometrial Explants to Prolonged Mechanical Stretch. Moraitis AA; Cordeaux Y; Charnock-Jones DS; Smith GC Endocrinology; 2015 Oct; 156(10):3511-6. PubMed ID: 26207346 [TBL] [Abstract][Full Text] [Related]
14. Vasopressin and oxytocin receptors on plasma membranes from rat mammary gland. Demonstration of vasopressin receptors by stimulation of inositol phosphate formation, and oxytocin receptors by binding of a specific 125I-labeled oxytocin antagonist, d(CH2)5(1)[Tyr(Me)2, Thr4,Tyr-NH2(9)]OVT. Soloff MS; Fernström MA; Fernström MJ Biochem Cell Biol; 1989; 67(2-3):152-62. PubMed ID: 2546575 [TBL] [Abstract][Full Text] [Related]
15. Spontaneous contractions of myometrium from humans, non-human primate and rodents are sensitive to selective oxytocin receptor antagonism in vitro. Wilson RJ; Allen MJ; Nandi M; Giles H; Thornton S BJOG; 2001 Sep; 108(9):960-6. PubMed ID: 11563467 [TBL] [Abstract][Full Text] [Related]
16. Comparison of vasopressin and oxytocin receptors in the rat uterus and vascular tissue. Anouar A; Clerget MS; Durroux T; Barberis C; Germain G Eur J Pharmacol; 1996 Jul; 308(1):87-96. PubMed ID: 8836636 [TBL] [Abstract][Full Text] [Related]
17. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. Borthwick AD; Davies DE; Exall AM; Livermore DG; Sollis SL; Nerozzi F; Allen MJ; Perren M; Shabbir SS; Woollard PM; Wyatt PG J Med Chem; 2005 Nov; 48(22):6956-69. PubMed ID: 16250654 [TBL] [Abstract][Full Text] [Related]
18. FE 200 440: a selective oxytocin antagonist on the term-pregnant human uterus. Nilsson L; Reinheimer T; Steinwall M; Akerlund M BJOG; 2003 Nov; 110(11):1025-8. PubMed ID: 14592588 [TBL] [Abstract][Full Text] [Related]
19. Comparison of in vitro and in vivo inhibitory effects of peptide and nonpeptide oxytocin antagonists on radioligand binding and uterine contractility of rats during pregnancy. Kawarabayashi T; Kobayashi M; Akahane M; Ajisawa Y Am J Obstet Gynecol; 1996 Nov; 175(5):1348-55. PubMed ID: 8942513 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo pharmacological characterization of ethyl-4-[trans-4-[((2S)-2-hydroxy-3-[4-hydroxy-3[(methylsulfonyl)amino]-phenoxy]propyl) amino]cyclohexyl]benzoate hydrochloride (SAR150640), a new potent and selective human beta3-adrenoceptor agonist for the treatment of preterm labor. Croci T; Cecchi R; Marini P; Rouget C; Viviani N; Germain G; Guagnini F; Fradin Y; Descamps L; Pascal M; Advenier C; Breuiller-Fouché M; Leroy MJ; Bardou M J Pharmacol Exp Ther; 2007 Jun; 321(3):1118-26. PubMed ID: 17351104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]